These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 28494171)

  • 1. Zinc oxide nanoparticles antagonize the effect of Cetuximab on head and neck squamous cell carcinoma in vitro.
    Gehrke T; Scherzad A; Ickrath P; Schendzielorz P; Hagen R; Kleinsasser N; Hackenberg S
    Cancer Biol Ther; 2017 Jul; 18(7):513-518. PubMed ID: 28494171
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Zinc oxide nanoparticles induce photocatalytic cell death in human head and neck squamous cell carcinoma cell lines in vitro.
    Hackenberg S; Scherzed A; Kessler M; Froelich K; Ginzkey C; Koehler C; Burghartz M; Hagen R; Kleinsasser N
    Int J Oncol; 2010 Dec; 37(6):1583-90. PubMed ID: 21042728
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interleukin-1 alpha increases anti-tumor efficacy of cetuximab in head and neck squamous cell carcinoma.
    Espinosa-Cotton M; Rodman Iii SN; Ross KA; Jensen IJ; Sangodeyi-Miller K; McLaren AJ; Dahl RA; Gibson-Corley KN; Koch AT; Fu YX; Badovinac VP; Laux D; Narasimhan B; Simons AL
    J Immunother Cancer; 2019 Mar; 7(1):79. PubMed ID: 30890189
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antitumor activity of photo-stimulated zinc oxide nanoparticles combined with paclitaxel or cisplatin in HNSCC cell lines.
    Hackenberg S; Scherzed A; Harnisch W; Froelich K; Ginzkey C; Koehler C; Hagen R; Kleinsasser N
    J Photochem Photobiol B; 2012 Sep; 114():87-93. PubMed ID: 22722055
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cetuximab sensitivity of head and neck squamous cell carcinoma xenografts is associated with treatment-induced reduction in EGFR, pEGFR, and pSrc.
    Jedlinski A; Garvin S; Johansson AC; Edqvist PH; Ponten F; Roberg K
    J Oral Pathol Med; 2017 Oct; 46(9):717-724. PubMed ID: 28036101
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual Targeting of Epidermal Growth Factor Receptor and HER3 by MEHD7945A as Monotherapy or in Combination with Cisplatin Partially Overcomes Cetuximab Resistance in Head and Neck Squamous Cell Carcinoma Cell Lines.
    De Pauw I; Wouters A; Van den Bossche J; Deschoolmeester V; Baysal H; Pauwels P; Peeters M; Vermorken JB; Lardon F
    Cancer Biother Radiopharm; 2017 Sep; 32(7):229-238. PubMed ID: 28910149
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor-Specific Antibody, Cetuximab, Enhances the
    Jin WJ; Erbe AK; Schwarz CN; Jaquish AA; Anderson BR; Sriramaneni RN; Jagodinsky JC; Bates AM; Clark PA; Le T; Lan KH; Chen Y; Kim K; Morris ZS
    Front Immunol; 2020; 11():591139. PubMed ID: 33281820
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HER3 Targeting Sensitizes HNSCC to Cetuximab by Reducing HER3 Activity and HER2/HER3 Dimerization: Evidence from Cell Line and Patient-Derived Xenograft Models.
    Wang D; Qian G; Zhang H; Magliocca KR; Nannapaneni S; Amin AR; Rossi M; Patel M; El-Deiry M; Wadsworth JT; Chen Z; Khuri FR; Shin DM; Saba NF; Chen ZG
    Clin Cancer Res; 2017 Feb; 23(3):677-686. PubMed ID: 27358485
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypoxia Mediates Differential Response to Anti-EGFR Therapy in HNSCC Cells.
    Wiechec E; Hansson KT; Alexandersson L; Jönsson JI; Roberg K
    Int J Mol Sci; 2017 Apr; 18(5):. PubMed ID: 28468237
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epidermal growth factor receptor variant III in head and neck squamous cell carcinoma is not relevant for targeted therapy and irradiation.
    Thomas Koch D; Pickhard A; Gebel L; Buchberger AMS; Bas M; Mogler C; Reiter R; Piontek G; Wirth M
    Oncotarget; 2017 May; 8(20):32668-32682. PubMed ID: 28427242
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gene status of head and neck squamous cell carcinoma cell lines and cetuximab-mediated biological activities.
    Kondo N; Tsukuda M; Taguchi T; Nakazaki K; Sakakibara A; Takahashi H; Toth G; Nishimura G
    Cancer Sci; 2011 Sep; 102(9):1717-23. PubMed ID: 21631644
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nanoparticle-induced photocatalytic head and neck squamous cell carcinoma cell death is associated with autophagy.
    Hackenberg S; Scherzed A; Gohla A; Technau A; Froelich K; Ginzkey C; Koehler C; Burghartz M; Hagen R; Kleinsasser N
    Nanomedicine (Lond); 2014 Jan; 9(1):21-33. PubMed ID: 23731458
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decreased SMAD4 expression is associated with induction of epithelial-to-mesenchymal transition and cetuximab resistance in head and neck squamous cell carcinoma.
    Cheng H; Fertig EJ; Ozawa H; Hatakeyama H; Howard JD; Perez J; Considine M; Thakar M; Ranaweera R; Krigsfeld G; Chung CH
    Cancer Biol Ther; 2015; 16(8):1252-8. PubMed ID: 26046389
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CCI-779 (Temsirolimus) exhibits increased anti-tumor activity in low EGFR expressing HNSCC cell lines and is effective in cells with acquired resistance to cisplatin or cetuximab.
    Niehr F; Weichert W; Stenzinger A; Budach V; Tinhofer I
    J Transl Med; 2015 Apr; 13():106. PubMed ID: 25890004
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The hypoxic tumor microenvironment and drug resistance against EGFR inhibitors: preclinical study in cetuximab-sensitive head and neck squamous cell carcinoma cell lines.
    Boeckx C; Van den Bossche J; De Pauw I; Peeters M; Lardon F; Baay M; Wouters A
    BMC Res Notes; 2015 Jun; 8():203. PubMed ID: 26032726
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenomic correlates of response to cetuximab monotherapy in head and neck squamous cell carcinoma.
    Faden DL; Concha-Benavente F; Chakka AB; McMichael EL; Chandran U; Ferris RL
    Head Neck; 2019 Aug; 41(8):2591-2601. PubMed ID: 30828910
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuregulin Signaling Is a Mechanism of Therapeutic Resistance in Head and Neck Squamous Cell Carcinoma.
    Baro M; Lopez Sambrooks C; Burtness BA; Lemmon MA; Contessa JN
    Mol Cancer Ther; 2019 Nov; 18(11):2124-2134. PubMed ID: 31387891
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The cancer pain related factors affected by celecoxib together with cetuximab in head and neck squamous cell carcinoma.
    Yang Y; Yan J; Huang Y; Xu H; Zhang Y; Hu R; Jiang J; Chen Z; Jiang H
    Biomed Pharmacother; 2015 Mar; 70():181-9. PubMed ID: 25776499
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and preclinical investigation of
    Shah SQ; Gul-E-Raana
    Mol Biol Rep; 2019 Apr; 46(2):1675-1682. PubMed ID: 30680596
    [TBL] [Abstract][Full Text] [Related]  

  • 20. STING activation enhances cetuximab-mediated NK cell activation and DC maturation and correlates with HPV
    Lu S; Concha-Benavente F; Shayan G; Srivastava RM; Gibson SP; Wang L; Gooding WE; Ferris RL
    Oral Oncol; 2018 Mar; 78():186-193. PubMed ID: 29496049
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.